Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D

 April 1, 2026

Pharmaceutical Technology

Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.

Clinical DataCardiovascularRead full story

Post navigation

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes →
← Viridian reports positive results from elegrobart phase 3 trial

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com